216 related articles for article (PubMed ID: 30798622)
21. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse.
Gisbert JP; Bermejo F; Pérez-Calle JL; Taxonera C; Vera I; McNicholl AG; Algaba A; López P; López-Palacios N; Calvo M; González-Lama Y; Carneros JA; Velasco M; Maté J
Inflamm Bowel Dis; 2009 Aug; 15(8):1190-8. PubMed ID: 19291780
[TBL] [Abstract][Full Text] [Related]
22. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease.
Canani RB; Terrin G; Rapacciuolo L; Miele E; Siani MC; Puzone C; Cosenza L; Staiano A; Troncone R
Dig Liver Dis; 2008 Jul; 40(7):547-53. PubMed ID: 18358796
[TBL] [Abstract][Full Text] [Related]
23. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission.
Mooiweer E; Severs M; Schipper ME; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
J Crohns Colitis; 2015 Jan; 9(1):50-5. PubMed ID: 25518048
[TBL] [Abstract][Full Text] [Related]
24. Role of fecal calprotectin testing to predict relapse in teenagers with inflammatory bowel disease who report full disease control.
van Rheenen PF
Inflamm Bowel Dis; 2012 Nov; 18(11):2018-25. PubMed ID: 22275341
[TBL] [Abstract][Full Text] [Related]
25. Fecal hemoglobin and calprotectin are equally effective in identifying patients with inflammatory bowel disease with active endoscopic inflammation.
Mooiweer E; Fidder HH; Siersema PD; Laheij RJ; Oldenburg B
Inflamm Bowel Dis; 2014 Feb; 20(2):307-14. PubMed ID: 24374878
[TBL] [Abstract][Full Text] [Related]
26. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
[TBL] [Abstract][Full Text] [Related]
27. Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: expert clinical opinion.
Rogler G; Aldeguer X; Kruis W; Lasson A; Mittmann U; Nally K; Peyrin-Biroulet L; Schoepfer A; Vatn M; Vavricka S; Logan R
J Crohns Colitis; 2013 Sep; 7(8):670-7. PubMed ID: 23517932
[No Abstract] [Full Text] [Related]
28. Fecal calprotectin for the prediction of small-bowel Crohn's disease by capsule endoscopy: a systematic review and meta-analysis.
Kopylov U; Yung DE; Engel T; Avni T; Battat R; Ben-Horin S; Plevris JN; Eliakim R; Koulaouzidis A
Eur J Gastroenterol Hepatol; 2016 Oct; 28(10):1137-44. PubMed ID: 27415156
[TBL] [Abstract][Full Text] [Related]
29. Rapid fecal calprotectin testing to assess for endoscopic disease activity in inflammatory bowel disease: A diagnostic cohort study.
Kwapisz L; Mosli M; Chande N; Yan B; Beaton M; Micsko J; Mennill PW; Barnett W; Bax K; Ponich T; Howard J; Tirolese A; Lannigan R; Gregor J
Saudi J Gastroenterol; 2015; 21(6):360-6. PubMed ID: 26655130
[TBL] [Abstract][Full Text] [Related]
30. The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease.
Kwapisz L; Gregor J; Chande N; Yan B; Ponich T; Mosli M
Scand J Gastroenterol; 2017 Aug; 52(8):846-850. PubMed ID: 28423962
[TBL] [Abstract][Full Text] [Related]
31. Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review.
Alibrahim B; Aljasser MI; Salh B
Can J Gastroenterol Hepatol; 2015 Apr; 29(3):157-63. PubMed ID: 25855880
[TBL] [Abstract][Full Text] [Related]
32. Noninvasive Fecal Immunochemical Testing and Fecal Calprotectin Predict Mucosal Healing in Inflammatory Bowel Disease: A Prospective Cohort Study.
Ma C; Lumb R; Walker EV; Foshaug RR; Dang TT; Verma S; Huang VW; Kroeker KI; Wong K; Dieleman LA; Fedorak RN; Halloran BP
Inflamm Bowel Dis; 2017 Sep; 23(9):1643-1649. PubMed ID: 28644184
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the Liaison® Calprotectin kit with a well established point of care test (Quantum Blue - Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up.
Delefortrie Q; Schatt P; Grimmelprez A; Gohy P; Deltour D; Collard G; Vankerkhoven P
Clin Biochem; 2016 Feb; 49(3):268-73. PubMed ID: 26506117
[TBL] [Abstract][Full Text] [Related]
34. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings.
Sipponen T; Savilahti E; Kolho KL; Nuutinen H; Turunen U; Färkkilä M
Inflamm Bowel Dis; 2008 Jan; 14(1):40-6. PubMed ID: 18022866
[TBL] [Abstract][Full Text] [Related]
35. The semi-quantitative calprotectin rapid test--is it useful in inflammatory bowel disease?
Dranga M; Dumitrescu G; Badea M; Blaj A; Mihai C; Prelipcean CC
Rev Med Chir Soc Med Nat Iasi; 2012; 116(3):761-5. PubMed ID: 23272524
[TBL] [Abstract][Full Text] [Related]
36. Faecal calprotectin: a new marker for Crohn's disease?
Wassell J; Dolwani S; Metzner M; Losty H; Hawthorne A
Ann Clin Biochem; 2004 May; 41(Pt 3):230-2. PubMed ID: 15117438
[TBL] [Abstract][Full Text] [Related]
37. Use of biomarkers in inflammatory bowel disease.
Egea Valenzuela J; Antón Ródenas G; Sánchez Martínez A
Med Clin (Barc); 2019 Apr; 152(8):310-316. PubMed ID: 30502302
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndrome.
Otten CM; Kok L; Witteman BJ; Baumgarten R; Kampman E; Moons KG; de Wit NJ
Clin Chem Lab Med; 2008; 46(9):1275-80. PubMed ID: 18597588
[TBL] [Abstract][Full Text] [Related]
39. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease.
Kopylov U; Rosenfeld G; Bressler B; Seidman E
Inflamm Bowel Dis; 2014 Apr; 20(4):742-56. PubMed ID: 24562174
[TBL] [Abstract][Full Text] [Related]
40. Role of capsule endoscopy and fecal biomarkers in small-bowel Crohn's disease to assess remission and predict relapse.
Aggarwal V; Day AS; Connor S; Leach ST; Brown G; Singh R; Friedman A; Zekry A; Craig PI
Gastrointest Endosc; 2017 Dec; 86(6):1070-1078. PubMed ID: 28947363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
